- Title:
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
- Authors:
- Source:
- In Annals of Oncology April 2020 31(4):507-516
- Academic Journal
Dear user, the application need JavaScript support. Please enable JavaScript in your browser.